ARDELYX INC
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
ARDX$2.88-3.7%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Plans
During the three months ended December 31, 2023, our Section 16 officers and directors adopted orterminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
| Name and Title of Director or Officer | Action | Date | Trading Arrangement | Total Shares Available to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Rule 10b5-1* | Non-Rule 10b5-1** | ||||
| Michael Raab, President and Chief Executive Officer | Adoption | December 13, 2023 | X | 331,300 | January 6, 2025 |
| Elizabeth Grammer, Chief Legal Officer | Adoption | December 20, 2023 | X | 131,000 | July 16, 2024 |
| Robert Blanks, Chief Regulatory Officer | Adoption | December 21, 2023 | X | 48,000 | June 21, 2024 |
| Laura Williams, Chief Medical Officer | Adoption | December 27, 2023 | X | 79,949 | March 27, 2024 |
| *Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) | |||||
| ** Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.